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Abstract: 
Objective:  To investigate whether use of a Heat and Moisture Exchanger (HME) preserve 
body temperature in dogs weighing < 10kg anaesthetised for MRI. 
Study design: prospective, randomised, clinical trial. 
Animals: Thirty one client owned dogs (17 females, 14 males), 8 months-11 years old, 
weighing between 2.5 kg and 10 kg. 
Methods: Dogs were randomly assigned to a treatment group (HME (n= 16) or no HME 
(n=15)). Dogs were pseudorandomized according to the premedication they received, either 
dexmedetomidine or no dexmedetomidine. Induction agents were not standardised. General 
anaesthesia was maintained with isoflurane vaporised in 100% oxygen delivered using a T- 
piece and a fresh gas flow of 600 ml kg-1 minute-1. Rectal temperature was measured before 
premedication (T1), after induction (T2), before moving to the MRI unit (T3) and at the end 
of the MRI scan (T4). Ambient temperatures were measured in the induction room, outside 
and inside the MRI unit. Data were analysed using a General Linear Model (GLM) with T4, 
as the outcome variable.  Linear correlations were performed between T1, T2, T3 and T4 and 
variables that predicted T4 were investigated. 
  
Results:   Gender, age or body mass were not significantly different between groups. There 
were no significant differences in rectal temperature between groups at any time point 
(HMEend MRI= 36.26 ± 1.05 °C, No HMEend MRI = 36.24 ± 1.41 °C) but dogs receiving 
dexmedetomidine (DEXend MRI  = 36.6 ± 0.7 °C) had a higher rectal temperature compared to 
dogs that did not receive dexmedetomidine (No DEXend MRI = 35.9 ± 1.6 °C) for 
premedication. Rectal temperature varied directly with ambient temperature in MRI scanning 
room and inversely with anaesthetic duration.    
  
 
Conclusions and Clinical Relevance: Using a HME did not alter body temperature in dogs 
weighing less than 10 kg undergoing an MRI but including dexmedetomidine in the 
premedication regimen can preserve the body temperature during anaesthesia.  
Keywords: MRI, Heat and Moisture Exchanger, hypothermia, dexmedetomidine, dogs  
  
Introduction: 
Post-anaesthetic hypothermia is very common in small animals (Redondo et al. 2012a; 
Redondo et al. 2012b). Recent retrospective studies estimate the frequency of hypothermia to 
be 97.4 % and 83.6 %, respectively, for cats and dogs when hypothermia is defined as T° < 
38.5 °C (Redondo et al. 2012a; Redondo et al. 2012b). However normothermia for dogs and 
cats has also been previously described as 37.8°C-39.2 °C (Armstrong et al. 2005) so this 
prevalence of hypothermia might be an overestimation. However there appears to be no 
overall agreement in the literature about the definition of hypothermia in small animals.  
Hypothermia has a myriad of effects on body systems. For example it can affect the 
cardiovascular system to cause bradycardia, arrhythmias and hypotension; the respiratory 
system to cause hypoventilation, apnoea and hypoxaemia; the metabolic and endocrine 
systems to decrease metabolic rate, and reduce the efficacy of the coagulation cascade, and 
the immune system to increase the risk of wound infection (Armstrong et al. 2005). Many 
studies in small animals (Cabell et al. 1997; Machon et al. 1999; Kibanda & Gurney 2012; 
Clark-Price et al. 2013) have shown that active warming techniques such as heat mats and 
forced warm-air blankets are effective at preventing or treating perioperative hypothermia. 
However, preservation of body temperature during anaesthesia in patients undergoing MRI is 
problematic. MRI scanners use magnetic fields and radio waves to form images of the body. 
Therefore all electrical devices used in MRI scanners have to be non-magnetic and 
electrically non-conductive. To the authors’ knowledge, none of the currently available active 
warming devices are MRI compatible. Maintenance of normothermia is one of the key goals 
of supportive practices during anaesthesia. The only option to support body temperature 
when animals are undergoing an MRI scan is to use passive warming devices that are 
compatible with MRI technology. Another feature of MRI rooms is their low temperature, 
which is mandatory to keep the magnet cool. 
  
Heat and Moisture Exchangers (HME) are disposable devices placed between the patient and 
the breathing system. The exchanging medium is composed of foam, paper, or a substance 
that acts as a condensation and absorption surface. This medium is enclosed in plastic 
housing. There is also commonly a port built into the plastic housing to allow a gas sampling 
line for a respiratory gas monitor to be attached.  The aim of the device is to conserve exhaled 
water and heat and return it to the patient in the inspired gas (Dorsch & Dorsch 2014). There 
are no clinical data in the literature regarding the efficacy of HMEs in preservation of body 
temperature when used alone (i.e. without external warming devices such as heat mats) in 
small animals < 10 kg.        
Perioperative hypothermia develops in 3 phases (Armstrong et al. 2005). The first phase, 
which happens during the first hour of anaesthesia, is a rapid decrease in body temperature 
due to redistribution of heat from the core to the peripheral compartment. This redistribution 
is promoted by two mechanisms: the reduction in threshold temperature required to cause 
reflex vasoconstriction and by the direct vasodilation induced by anaesthetic agents. The 
second phase is characterised by a slow decrease in body temperature due to an imbalance 
between heat loss (evaporation, conduction, convection and radiation) and heat production. 
During the third phase, body temperature stabilises because of equal heat loss and heat 
production. As Sinclair (2003) suggested, it is believed that anaesthetic drugs with 
vasoconstrictor properties might decrease the heat loss that happens during the first phase. 
Vainionpää et al. (2013) confirmed this hypothesis in an experimental setting in 
medetomidine sedated dogs.  
The primary aim of this study was to investigate the efficacy of HMEs to maintain 
normothermia in dogs < 10 kg bodymass undergoing anaesthesia for MRI. We hypothesised 
that dogs receiving an HME would maintain a higher rectal body temperature than dogs that 
did not receive an HME in the anaesthetic breathing system.  
  
A secondary aim was to test the hypothesis that anaesthetised dogs receiving 
dexmedetomidine for premedication would have a smaller decrease in rectal temperature than 
dogs that did not receive dexmedetomidine as part of their premedication protocol.  
Materials and methods 
Dogs 
A prospective, pseudorandomised, clinical trial on 31 client-owned dogs weighing less than 
10 kg and requiring general anaesthesia (GA) for an MRI scan was conducted. The American 
Society of Anesthesiologists (ASA) physical status grade was also recorded but was not part 
of the inclusion criteria.  This study was approved by the University of **** ethical 
committee (VIN/13/028). Study-specific owner consent was not considered necessary by the 
institution’s ethics committee because anaesthetists were free to choose between routinely 
used sedative and anaesthetic medications and the consent to participate in the study was 
covered by the clinic’s general client consent form. The inclusion criteria for the study were 
that animals weighed between 2.5 kg and 10 kg, had intravenous access established with an 
intravenous catheter before premedication, and tolerated rectal measurement of body 
temperature. Dogs with hypothermia (< 37.8°C) or hyperthermia (> 39.2°C) before 
premedication were excluded from the study. 
 
Procedures:  
Due to the clinical nature of the study, it was problematic to standardise the anaesthesia 
protocol for all dogs that entered the study, therefore the anaesthesia protocol was matched 
between cases receiving an HME ( figure 1) (HME group) and the control group (no HME). 
Hence true randomisation of cases recruited to the study was not possible, but 
pseudorandomisation ensured that there was the same number of cases receiving 
  
dexmedetomidine for premedication in the group with the HME and the group without the 
HME. Thus two randomisation charts were used, one for dogs premedicated with 
dexmedetomidine and the other for dogs not premedicated with dexmedetomidine. Following 
a complete physical examination by a clinical anaesthetist, dogs were randomly allocated to 
group (HME or No HME) according to the premedication used (dexmedetomidine or not).  
Dose and choice of the premedication and induction agent were at the discretion of the 
clinician in charge of the case. All dogs received an opioid, which was most commonly 
butorphanol. Dexmedetomidine dose, in those patients that received it, ranged between 1 and 
10 μg kg-1. Anaesthesia was induced in all dogs with either propofol or alfaxalone 
administered to effect to allow orotracheal intubation. Anaesthesia was maintained with 
isoflurane (IsoFlo; Abbott, UK) in 100 % oxygen, and the isoflurane concentration was 
adjusted to achieve an adequate depth. All dogs were connected to a T-piece non-rebreathing 
system with a fresh gas flow of 600 ml kg-1 min-1. All patients received 5 ml kg-1 hour-1 
Hartmann’s solution (Vetivex 11, Dechra Veterinary Products Ltd, Shrewsbury, UK). In case 
of hypotension (defined as mean arterial pressure (MAP) < 60 mmHg) or evidence of 
hypovolaemia (heart rate (HR) > 150 beats per minute), a fluid bolus was administered and 
the volume recorded.  
 
Rectal temperature was recorded at a number of time points before and during anaesthesia 
(figure 2): before premedication (T1), immediately after induction of anaesthesia (T2), before 
the dog entered the bore of the MRI magnet (T3), and just after leaving the bore of the MRI 
magnet (T4) using a single, rapid response rectal thermometer (WelchAllyn SureTemp plus; 
WelshAllyn, Republic of Ireland). 
The ambient temperature in the anaesthesia induction area, ambient outdoor environmental 
temperature (animals had to be transported outdoors to enter the MRI unit) and the 
  
temperature in the MRI unit (both before and after the MRI scan) were recorded. Figure 2 
summarises each important time point of the temperature recording. 
All animals were wrapped in a single, standardised fleece blanket (Pet blanket fleece; 
DWDUK) following premedication until the end of the MRI scan. Length of anaesthesia 
(between induction and end of MRI) was recorded. The study ended at the end of the MRI 
scan. 
 
Statistical analysis: 
A sample size calculation indicated that a total of 64 animals (32 per arm) were required to 
have an 80 % power at α = 0.05 to detect a difference of 1 °C in rectal temperature, the 
minimum temperature difference considered to be clinically relevant. Unfortunately, mid-
way through the study MRI unit was changed preventing collection of this number of cases. 
However data collected at this time point were analysed. Confidence intervals indicated that 
the current sample size was sufficient to show a difference in rectal temperature of less than 
1 °C between groups. 
A General Linear Model (GLM) analysis, which combined a variance analysis and a 
covariance analysis adjusting for continuous variables, was carried out. The normality of the 
residual error and the homogeneity of the variance were checked to ensure that the modelling 
approach was appropriate. The use of HME and dexmedetomidine were entered into the 
model as categorical variables, each with two levels. The initial temperature of the dog (T1), 
the outdoor temperature, the duration of the MRI, the mean MRI unit temperature  and the 
body weight were tested as covariates within the model. All analyses were performed using 
SPSS for Windows (IBM SPSS statistic version 21).  
 A Mann-Whitney U test was used to check randomisation of the baseline variables (ASA 
grade, gender, the region of the MRI scan, induction agent used and the body condition score 
  
(BCS)) and a t-test to check the continuous baseline variables (body mass and age). P-values 
≤ 0.05 were considered statistically significant. 
 
Results: 
A total of 31 dogs, weighing (mean ± SD) 6.2 ± 2.2 kg were recruited to this study. The ages 
of dogs were relatively uniformly distributed from 8 to 132 months with a median age of 60 
months. Respectively, 16 and 15 dogs were included in the HME and No HME groups. Eight 
dogs in each group (HME and No HME) received dexmedetomidine as part of their 
premedication protocol. Each group comprised a wide distribution of breeds that precluded 
inclusion of breed in the statistical analysis. The breeds represented within each group are 
shown in Table 1. No significant differences were found between the age, body mass, BCS, 
ASA status and MRI scan region when dogs in the HME and No HME groups were 
compared. Dogs that received dexmedetomidine had significantly lower ASA status (i.e. were 
more likely to be systemically healthy) than dogs that were premedicated with other sedative 
agents (p = 0.02). 
The patients’ characteristics in each group are summarized in Table 1.  
Table 2 presents the results of the GLM used to analyse factors affecting rectal temperature at 
the end of anaesthesia in dogs receiving an HME or no HME throughout anaesthesia. It 
shows that the use of an HME did not affect the rectal temperature at the end of the MRI scan 
(T4).  Dogs that were not premedicated with dexmedetomidine had a significantly greater 
decrease in rectal temperature between T1 and T4. Body mass and MRI ambient temperature 
had a significant positive correlation with rectal temperature. Increasing the body mass by 1 
kg, or the temperature in the MRI by 1°C, was associated with an increase in the rectal 
temperature at the end of the MRI by 0.3 °C.  
  
The statistical modelling process also produced a predictive mathematical equation which 
may be used to construct an estimated mean of the rectal temperature at the end of the MRI 
for any combination of treatment or study variables (within the ranges measured within the 
study).  For example, if a dog was not premedicated with dexmedetomidine and did not 
receive an HME, rectal temperature at the end of the MRI scan would be equal to the 
intercept added to the product of B and each variable no HME, no dexmedetomidine, 
duration of MRI scan in minutes, ambient temperature (both MRI unit and outdoor), body 
temperature, body mass. B is the estimation of the effect of the parameter. For this dog the 
equation would be (table 2): 
Tend = 25.576 - 0.395 -0.716 + (Tbefore x 0.137 ) + (TMRI x 0.286 ) – (duration MRI  x 0.024) –
(Toutdoor x 0.073). 
There were no significant differences in ambient temperatures recorded in the induction room, 
outdoors, and in the MRI unit at the start and the end of the MRI scan, between each group. 
Figure 3 presents the mean (±SD) rectal temperature before premedication, after induction of 
anaesthesia, before entering the MRI unit and at the end of the MRI scan for each group. The 
lowest and the highest rectal temperatures recorded at the end of the MRI scan were 32.4° C 
and 37.7° C, respectively. Rectal temperature before premedication was significantly higher 
in dogs receiving dexmedetomidine for premedication. All dogs showed a significant 
decrease in rectal temperature when the rectal temperature before premedication and at the 
end of MRI were compared (p <0.001). Most of the dogs in each group, irrespective of 
premedication choice, had a rectal temperature at the end of the MRI scan below 37° C. 
 
Discussion: 
  
Perioperative hypothermia is a common complication in small animal anaesthesia (Redondo 
et al. 2012a; Redondo et al. 2012b). Efficient warming devices all need an electricity source 
and are therefore not compatible with an MRI scanner. Therefore the first aim of our study 
was to evaluate a passive warming device compatible with MRI technology, the HME, in 
dogs weighing less than 10 kg anaesthetised for an MRI scan. Sinclair (2003) suggested that 
use of an alpha2-agonist for premedication could decrease heat loss by redistribution. This 
hypothesis was confirmed by Vainionpää et al. (2013) in experimental beagle dogs sedated 
with medetomidine. Therefore our secondary aim was to confirm this hypothesis in a clinical 
setting in anaesthetised dogs. 
All dogs recruited to the study were scheduled to undergo anaesthesia for an MRI scan of the 
brain or spinal cord. As such, although all dogs weighed less than 10 kg, a wide variety of 
breeds and ages of dogs of both gender were recruited. Our population was therefore 
heterogeneous, which made it a good representative of the wider clinical situation. All dogs 
had a statistically significant reduction in rectal temperature at the end of the MRI scan when 
compared with rectal temperature before premedication. The use of an HME did not 
significantly alter rectal temperature at the end of anaesthesia.  However, dogs that received 
dexmedetomidine for premedication had a higher rectal temperature at the end of anaesthesia 
than dogs that did not receive dexmedetomidine, independent of use of an HME or not.   
To the authors’ knowledge, only one study regarding the use of HMEs in dogs has been 
published in the veterinary literature (Hofmeister et al. 2011). This study also found that the 
inclusion of an HME in the breathing system did not facilitate maintenance of rectal 
temperature. However, Hofmeister et al. (2011), studied a patient population (dogs weighing 
at least 15 kg undergoing single-limb orthopaedic procedures) different to the present study. 
Additional heating methods were also used to warm the dogs. In the human field, HMEs are 
widely used to maintain the humidity of the airway and to decrease the risk of pneumonia 
  
during long term mechanical ventilation in the ICU or during a prolonged general anaesthesia. 
Only a few studies have investigated the effect of an HME on body temperature of human 
patients. Haslam and Nielsen (1986) studied the effect of an HME on the body temperature of 
men undergoing surgery lasting more than 2 hours. They found that patients receiving an 
HME maintained a higher body temperature. This finding was not affected by the fresh gas 
flow used (high or low). On the other hand, a study by Goldberg et al. (1988) in which 
patients were anaesthetised for more than 30 minutes but less than 90 minutes did not find 
any beneficial effect of HME on body temperature. HMEs are designed to reduce the heat 
loss by evaporation. Heat loss during general anaesthesia is divided in three phases 
(Armstrong et al. 2005). The first one occurs within the first hour of anaesthesia and is caused 
by the redistribution of heat from the core to the peripheral compartment. The second phase, 
which happens within the next two hours is due to heat loss from radiation, conduction, 
convection and evaporation, which exceeds the metabolic heat production. Therefore, the use 
of an HME to decrease heat loss by evaporation might be more evident during this phase. 
This could explain the different findings of the Goldberg and Haslam studies. The dogs in our 
study, were anaesthetised for up to 70 minutes, which corresponds to the end of the first 
phase or the start of the second phase. It is possible therefore that the effect of an HME to 
decrease heat loss by evaporation would be more apparent in patients anaesthetised for at 
least 2 hours. Also, many factors affect the efficacy of the HME; whether they are 
hydrophobic or hygroscopic (Dorsch & Dorsch 2014), the initial humidity of the gas, the 
fresh gas flow and the existence of a leak in the breathing system  (Gedeon et al. 1987).  In 
the human literature it is well described that hygroscopic HMEs have better heat conserving 
and exchanging properties than the hydrophobic HMEs used in our study (Eckerbom & 
Lindholm 1990; Sottiaux et al. 1993; Martin et al. 1994). Also the higher the fresh gas flow, 
the less efficient the HME is in conserving heat and moisture (Eckerbom & Lindholm 1990). 
  
As our patients were under 10 kg, we used a non-rebreathing breathing system necessitating a 
high fresh gas flow.  
An important finding in this study was that premedication with dexmedetomidine prevented, 
to some extent, a fall in rectal temperature during MRI. This has not been previously shown 
in a clinical setting in anaesthetised animals and may be another clinical benefit of the use of 
dexmedetomidine in very small patients which are known to be more prone to hypothermia 
because of their large surface area to mass ratio. The use of alpha-2-adrenoceptor agonist 
drugs is well described to cause a decrease in body temperature in human beings (Doufas et 
al. 2003) as well as in small animals (Ponder & Clark 1980; Livingston et al. 1984; Ansah et 
al. 1998; Vainionpää et al. 2013). It is believed that this decrease in body temperature is due 
to the depression of the central nervous system (CNS) associated with a decreased in 
muscular activity (MacDonald et al. 1988; Virtanen 1988). However, it was also suggested 
that the peripheral vasoconstriction produced by the administration of medetomidine might 
decrease the heat loss by redistribution (Sinclair 2003). This has been recently confirmed by 
Vainionpää et al. (2013) in experimental beagle dogs receiving a combination of 
medetomidine and butorphanol or medetomidine, butorphanol and MK-467. The latter group 
showed a lower rectal temperature. As MK-467 is a peripherally acting alpha-2-adrenergic 
antagonist, it was believed that this difference in body temperature might be because of a 
higher peripheral heat loss. Although dogs in our study treated with dexmedetomidine also 
had a higher baseline temperature before the administration of dexmedetomidine, the 
statistical model did not show any influence of the baseline temperature on the body 
temperature at the end of the MRI scan.  It is unknown why the baseline temperature was 
higher in the dogs receiving dexmedetomidine, but it could be hypothesized that in some 
cases anaesthetists may have chosen dexmedetomidine due to time constraints or patient 
temperament. For example, where a dog is presented the day prior to carrying out an MRI 
  
scan, it may be less likely to receive dexmedetomidine than a dog who is scheduled within a 
shorter period of time. Dogs undergoing MRI scanning on the same day as presentation may 
be held in the anaesthesia induction area pending pre-medication rather than be admitted to 
the frequently cooler ward.   
Dogs that received dexmedetomidine had a lower ASA grade probably because of the 
cardiovascular side effects of this class of drug (Murrell & Hellebrekers 2005). In a 
retrospective study (Redondo et al. 2012b), ASA III-IV dogs had a lower rectal temperature 
at the end of anaesthesia than ASA I dogs. They speculated that animals with a higher ASA 
grade are less likely to have an intact thermoregulatory mechanisms. This could be another 
confounding factor in the study. 
The analysis used in the present study also highlighted the effect of the duration of the MRI 
scan and the ambient temperature in the MRI unit on rectal temperature at the end of the MRI 
scan. The longer the MRI scan or the lower the ambient temperature, the greater the fall in 
rectal temperature. This has also been show previously  in dogs (Redondo et al. 2012b) and 
cats (Redondo et al. 2012a). Interestingly, our model failed to detect an effect of rectal 
temperature before premedication on subsequent rectal temperature.  
There are a number of limitations to our study which could have confounded the results. The 
duration of the MRI scan was not controlled between dogs, therefore it was included in the 
statistical model as a factor that may affect rectal temperature. The ambient environmental 
temperature and the temperature in the MRI scanner was also not controlled between animals 
and this would have increased the variability of data in this clinical study. Although the effect 
of dexmedetomidine was investigated in the statistical model other premedication or 
induction drugs were not standardised between animals. It is possible that some drugs cause 
more depression of the CNS control of body temperature than others. For example some dogs 
  
received acepromazine which causes vasodilation and could potentially worsen the heat loss. 
However, because every dog in the study received isoflurane, which also causes vasodilation, 
we hypothesized that the administration of acepromazine to some dogs would not affect our 
results. Similarly, opioids are also implicated in decrease in body temperature (Clark 1979). 
However, because all dogs received opioids as part of their premedication protocol, it is 
unlikely to have confounded the results of this study. On the other hand, this heterogeneity is 
a strength of the study as it is a good representation of the clinical situation. 
In conclusion, in the present study, the use of an HME did not preserve the rectal temperature 
in anaesthetised dogs weighing less than 10 kg undergoing MRI. Also, premedication with 
dexmedetomidine was associated with a better maintenance of the rectal temperature 
compared with dogs that received other drugs for premedication. This may be considered 
when making decisions about which premedication agent to use in patients of low body mass.  
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Figure 1. 
 
  
  
Figure 2 : Mean ( ± SE) ambient temperature in degrees Celsius at different time points for 
dogs receiving no HME and no dexmedetomidine, no HME and dexmedetomidine,  HME 
and no dexmedetomidine, HME and dexmedetomidine: 
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Figure 3: Mean ( ± SE) ambient temperature in degrees Celsius at 
different time points for dogs receiving no HME and no 
dexmedetomidine, no HME and dexmedetomidine,  HME and no 
dexmedetomidine, HME and dexmedetomidine: 
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Table 1: Patient characteristics (age (median [range]); body mass (mean ± SD); BCS (median 
[range]); reproductive status; breed; ASA grade), anaesthetic protocol, and reason for and the 
duration of the MRI scan in minutes (mean ±  SD): 
Variable  No HME (n = 15) HME (n = 16) 
 
No dex (n = 7) Dex (n = 8) No dex ( n = 8) Dex ( n = 8 ) 
Age (months) 53 [24-132] 66.5 [27-90] 73.5 [22-132] 53 [8-120] 
Bodymass (kg) 5 ± 3 7  ± 1 6  ± 2 5  ± 2 
BCS [1-9] 5 [4-6] 5 [3-7] 5 [3-6] 5 [2-7] 
     Gender  
   male 2 3 3 5 
female 5 4 5 3 
     Breed 
    Yorkshire terrier 1 0 1 1 
Chihuahua 2 0 0 1 
Jack Russell terrier 1 2 1 1 
Border terrier 2 0 1 0 
Shi tzu 1 2 1 0 
Cavalier King Charles 
spaniel 0 1 2 1 
Patterdale terrier 0 1 0 0 
Maltese terrier 0 1 0 2 
Cavapoo 0 1 0 0 
Dachshund 0 0 2 1 
Cocker spaniel 0 0 0 1 
     ASA grade 
    I 0 1 0 0 
  
II 5 7 6 8 
III 2 0 2 0 
IV 0 0 0 0 
V 0 0 0 0 
     Premedication 
   Acepromazine 
(0.02-0.03 mg kg-1) 
(ACP injection ;Novartis, 
UK) 4 0 2 0 
Butorphanol      
(0.2-0.4 mg kg-1) 
(Alvegesic vet; Dechra, 
UK) 2 6 6 5 
Methadone 
(0.2-0.4 mg kg-1) 
Comfortan; Dechra, UK) 5 2 2 2 
Buprenorphine (0.02mg 
kg-1) 
(Buprecare; Animalcare, 
UK) 0 0 0 1 
Midazolam  
(0.3-0.4 mg kg-1) 
(Hypnovel; Roche, UK) 0 0 3 0 
Dexmedetomidine  
(2-5.5 μg kg-1) 
(Dexdomitor 0.1; Orion 
Pharma, UK) 0 8 0 8 
Induction 
    Propofol  5 5 5 6 
  
(1.5-5.5 mg kg-1) 
(PropofloPlus; Abbott, 
UK) 
Alfaxalone  
(0.9-3 mg kg-1) 
(Alfaxan; Jurox, UK) 2 3 3 2 
     MRI region 
   Spine 4 5 4 4 
Brain 3 3 4 4 
Duration (min) 52 ± 30 65 ± 14 63 ± 28 70 ± 34 
SD = standard deviation; BCS = Body condition score; ASA grade = American Society of Anesthesiologist 
physical status classification 
 
  
  
Table 2: The parameter estimates from the fitted general linear model 
are shown together with their significance and a 95 % confidence 
interval:  use of HME, or not, and use of Dexmedetomidine or not, 
were entered as categorical variables, each with two levels. The MRI 
temperature, body mass, the initial rectal temperature of the dog (T1), 
the outdoor temperature, and the duration of the MRI were entered 
as covariates within the model. The parameter estimates can be used 
to construct an equation which summarises the mean (predicted) 
temperature for different combination/levels of the predictive 
variables (an example is given within the results section). 
Parameter B Std.Error t p-value 95 % Confidence Interval 
Lower 
bound 
Upper 
bound 
Intercept 25.576 13.743     
No HME - 0.395 0.287 - 1.380 0.181 - 0.988 0.197 
No 
dexmedetomidine 
- 0.716 0.342 - 2.093 0.048 -1.424 - 0.008 
MRI temperature 0.286 0.079 3.633 0.001 0.123 0.448 
Outdoor 
temperature 
- 0.073 0.037 - 1.951 0.063 - 0.150 0.004 
MRI duration -0.024 0.006 - 4.219 < 0.001 - 0.035 - 0.012 
Body mass 0.314 0.073 4.294 < 0.001 0.163 0.466 
Temperature 
before 
premedication 
0.137 0.353 0.388 0.702 - 0.594 0.868 
  
B = estimate of the effect size, thus as“No HME” is -0.395 this means that “No HME” is 0.194°C 
less than HME. When the variable is continuous,  for example, MRI temperature, then B is the size of 
the effect for a one unit change. So for MRI temperature where B = 0.286 this means that for every 
1°C increase in MRI temperature there is a 0.286 °C increase in rectal temperature at the end of the 
MRI scan. 
 
